Cancer Biology & Therapy · 2014 · 27 citations · 43 references
MedicineOncologyPharmacologyCancer PharmacologyOncology PharmacotherapySolid Tumor PharmacotherapyAngiogenesisAngiogenesis In CancerMalignant NeoplasmsPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsRenal Cell CarcinomaAngiogenic ResponseCombination Antiangiogenic TherapyVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor InhibitorsVascular Endothelial Growth Factor Receptor SignalingVascular Endothelial Growth Factor ReceptorsVegfr Inhibitors
Our prior phase I study of the combination of vascular endothelial growth factor (VEGF) antibody, bevacizumab, and VEGF receptor (VEGFR) inhibitor, sunitinib, in advanced solid tumors identified an encouraging response evaluation. An expansion phase of this study was thus undertaken to obtain further safety data, response assessment and characterization of pharmacodynamic biomarkers in melanoma, renal, and adrenal carcinoma patients. Patients with metastatic solid tumors received sunitinib (37.5 mg/d, 4 wk on/2 wk off) and bevacizumab (5 mg/kg intravenously every 2 wk). Responses were assessed every 2 cycles. Serum levels of angiogenic molecules were measured using ELISA assays. Twenty-two patients were enrolled, including 11 melanoma, 5 renal cell carcinoma (RCC), 5 adrenal cancer, and 1 angiosarcoma. Grade 3 or higher adverse events were observed in 15 patients, including hypertension (41%), thrombocytopenia (23%), and fatigue (14%). Three RCC patients, and 1 melanoma patient developed thrombotic microangiopathy (TMA). Partial response (PR) occurred in 21% patients, including melanoma (2), adrenal (1), and renal (1) carcinomas. Overall, 6 patients demonstrated some reduction in their tumor burden. Serum VEGF and several other proangiogenic proteins declined over the first 4 wk of treatment whereas the putative VEGF-resistant protein, prokineticin-2, increased over 10-fold. Occurrence of TMA related to dual VEGF/VEGFR inhibition can result from systemic or nephron specific injury even in non-renal malignancies. While the combination of sunitinib and bevacizumab was clinically efficacious in renal cell carcinoma and melanoma, the observance of microangiopathy, even in non-RCC patients, is a significant toxicity that precludes further clinical development.
43
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
David W. M. Leung, George Cachianes, Wun-Jing Kuang et al. · Science · 1989 · 5K citations
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Donald R. Senger, Stephen J. Galli, Ann M. Dvořàk et al. · Science · 1983 · 4K citations
Medicine, Biochemistry, Oncology +13
Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF
Pamela J. Keck, Scott D. Hauser, Gwen G. Krivi et al. · Science · 1989 · 2.1K citations
ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS
Judah Folkman, Ezio Merler, Charles M. Abernathy et al. · The Journal of Experimental Medicine · 1971 · 1.7K citations · Full text
Medicine, Cancer Biology, Oncology +15